Literature DB >> 18076934

Over expression of insulin-like growth factor binding protein 3 in clear cell renal cell carcinoma.

Shang-Tian Chuang1, Kurt T Patton, Kristian T Schafernak, Veronica Papavero, Fan Lin, Robert C Baxter, Bin Tean Teh, Ximing J Yang.   

Abstract

PURPOSE: We recently reported that IGFBP-3 (insulin-like growth factor binding protein 3) is one of the top genes that are over expressed in clear cell renal cell carcinoma. We further investigated IGFBP-3 expression in renal tumors using gene expression microarrays, immunohistochemistry and Western blotting.
MATERIALS AND METHODS: A total of 70 renal neoplasms were subjected to gene expression microarrays using gene chips containing 21,632 cDNA clones. IGFBP-3 expression was measured in each renal epithelial neoplasm. In addition, we performed immunohistochemistry for IGFBP-3 in 127 renal epithelial tumors, including 58 clear cell renal cell carcinomas. Moreover, IGFBP-3 staining intensity was evaluated to determine whether there was a correlation with Fuhrman grade. Lastly, Western blot was performed to confirm IGFBP-3 levels.
RESULTS: On microarray analysis of 70 renal neoplasms IGFBP-3 mRNA was increased in 63% of clear cell renal cell carcinomas (27 of 43) but in only 4% of other renal tumors (1 of 24). On immunohistochemistry 74% of clear cell renal cell carcinomas (43 of 58) showed IGFBP-3 immunoreactivity compared to only 9% of other renal neoplasms (6 of 69). High grade (Fuhrman grades 3 and 4) clear cell renal cell carcinomas showed higher IGFBP-3 staining intensity than low grade ones (15 of 17 vs 8 of 41). Western blot confirmed immunohistochemistry findings with the detection of high IGFBP-3 in clear cell renal cell carcinoma but not in other types of kidney tumors.
CONCLUSIONS: With a combination of cDNA microarrays, Western blot and immunohistochemistry we confirmed that IGFBP-3 is a marker for clear cell renal cell carcinoma. Furthermore, higher IGFBP-3 expression was associated with higher Fuhrman grade.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18076934     DOI: 10.1016/j.juro.2007.09.106

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  19 in total

1.  Involvement of insulin-like growth factor-binding protein-3 in the effects of histone deacetylase inhibitor MS-275 in hepatoma cells.

Authors:  Wen Hui Lin; Janet L Martin; Deborah J Marsh; Michelle M Jack; Robert C Baxter
Journal:  J Biol Chem       Date:  2011-07-07       Impact factor: 5.157

2.  Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development.

Authors:  Woo-Young Kim; Mi-Jung Kim; Hojin Moon; Ping Yuan; Jin-Soo Kim; Jong-Kyu Woo; Guangcheng Zhang; Young-Ah Suh; Lei Feng; Carmen Behrens; Carolyn S Van Pelt; Hyunseok Kang; J Jack Lee; Waun-Ki Hong; Ignacio I Wistuba; Ho-Young Lee
Journal:  Endocrinology       Date:  2011-03-29       Impact factor: 4.736

3.  Circulating levels of obesity-related markers and risk of renal cell carcinoma in the PLCO cancer screening trial.

Authors:  Linda M Liao; Jonathan N Hofmann; Eunyoung Cho; Michael N Pollak; Wong-Ho Chow; Mark P Purdue
Journal:  Cancer Causes Control       Date:  2017-05-08       Impact factor: 2.506

4.  Personalized characterization of diseases using sample-specific networks.

Authors:  Xiaoping Liu; Yuetong Wang; Hongbin Ji; Kazuyuki Aihara; Luonan Chen
Journal:  Nucleic Acids Res       Date:  2016-09-04       Impact factor: 16.971

5.  Involvement of the insulin-like growth factor binding proteins in the cancer cell response to DNA damage.

Authors:  Melissa W Y Chua; Mike Z Lin; Janet L Martin; Robert C Baxter
Journal:  J Cell Commun Signal       Date:  2015-01-25       Impact factor: 5.782

Review 6.  Noncoding RNA actions through IGFs and IGF binding proteins in cancer.

Authors:  Aidan Kerr; Robert C Baxter
Journal:  Oncogene       Date:  2022-05-21       Impact factor: 8.756

7.  Insulin-like growth factor binding protein-3 (IGFBP-3): Novel ligands mediate unexpected functions.

Authors:  Robert C Baxter
Journal:  J Cell Commun Signal       Date:  2013-08       Impact factor: 5.782

8.  FXYD3: A Promising Biomarker for Urothelial Carcinoma.

Authors:  Zhongfa Zhang; See-Tong Pang; Katherine A Kasper; Chunyan Luan; Bill Wondergem; Fan Lin; Cheng-Keng Chuang; Bin Tean Teh; Ximing J Yang
Journal:  Biomark Insights       Date:  2011-02-15

Review 9.  Metabolic syndrome and renal cell carcinoma.

Authors:  Gui-Ming Zhang; Yao Zhu; Ding-Wei Ye
Journal:  World J Surg Oncol       Date:  2014-07-29       Impact factor: 2.754

10.  An analysis of growth, differentiation and apoptosis genes with risk of renal cancer.

Authors:  Linda M Dong; Paul Brennan; Sara Karami; Rayjean J Hung; Idan Menashe; Sonja I Berndt; Meredith Yeager; Stephen Chanock; David Zaridze; Vsevolod Matveev; Vladimir Janout; Hellena Kollarova; Vladimir Bencko; Kendra Schwartz; Faith Davis; Marie Navratilova; Neonila Szeszenia-Dabrowska; Dana Mates; Joanne S Colt; Ivana Holcatova; Paolo Boffetta; Nathaniel Rothman; Wong-Ho Chow; Philip S Rosenberg; Lee E Moore
Journal:  PLoS One       Date:  2009-03-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.